NLA Resources
Knowledge Center
Membership Resources
Join the National Lipid Association, focused on enhancing the science and practice of lipidology to promote optimal cardiometabolic health.
After making your filter selections, please scroll down to see results.
S7E4: 2026 ACC/AHA Cholesterol (Dyslipidemia) Guidelines: Clinical Meaning for Lipidologists
Join host Dr. Peter H. Jones for a special episode of Lipid Insights discussing the 2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia. Dr. Jones is joined…
Managing Hypercholesterolemia in Adults Older Than 75 Years Without a History of Atherosclerotic Cardiovascular Disease: An Expert Clinical Consensus from the National Lipid Association and the American Geriatrics Society
Managing Hypercholesterolemia in Adults Older Than 75 Years Without a History of Atherosclerotic Cardiovascular Disease: An Expert Clinical Consensus from the National Lipid Association and…
S5E5: Managing Hypercholesterolemia in Adults Aged 75 Years and Older w/o a History of ASCVD: A Scientific Statement from the NLA & AGS
Listen to Dr. Brown discuss with Dr. Saseen the Scientific Statement from the NLA and the AGS on managing hypercholesterolemia in adults aged 57 and…
A New Vision for the NLA
The National Lipid Association owes much of its success to the founding lipid legend members, not only for their dedication to the organization but for…
Cholesterol Guidelines and NLA Involvement
The National Lipid Association remains focused on enhancing the practice of lipid management in clinical medicine, with guideline education and participation as a critical part…
NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient
NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient
Clinicians Should Monitor LDL-C After Starting Lipid-Lowering Therapy
Multiple randomized controlled trials have demonstrated significant reductions in major cardiovascular (CV) events and mortality with statin therapy.(1) These data have supported the “LDL-C treatment…
Enhancing the value of PCSK9 monoclonal antibodies by identifying patients most likely to benefit. A consensus statement from the National Lipid Association
Enhancing the value of PCSK9 monoclonal antibodies by identifying patients most likely to benefit. A consensus statement from the National Lipid Association